Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1478320 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $22.56Day +0.18%Mkt cap $3.6B1Y +117.1%Off 52W high −2.5%Vol (1Y) 69.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,779 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.1% of sh out |
| Days to cover4.3d |
| 13F net flow (QoQ)−1.10% |
| Top-10 13F concentration51.4% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$295.4M |
| Earnings (TTM)-$49.7M |
| ROE−28.2% |
| Net margin−21.5% |
| ROIC−15.7% |
| Debt / equity0.60× |
| Sales growth 3Y14.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+38.9% |
| 1Y+117.1% |
| 3Y+167.3% |
| 5Y−38.4% |
| Since incept. (ann.)−7.9% |
Total return through 2026-07-29 · series begins 2019-06-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.3% |
| Ann. volatility (3Y)77.2% |
| Sharpe (1Y)1.44 |
| Sharpe (3Y)0.82 |
| Max drawdown (1Y)−39.3% |
| Max drawdown (3Y)−72.3% |
| Beta (3Y vs SPY)2.00 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 30.0M | $416M | 18.74% | +0.0% |
| BlackRock, Inc. | 13.3M | $185M | 8.31% | −0.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.1M | $85M | 3.81% | new |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 5.4M | $75M | 3.40% | +33.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5M | $62M | 2.81% | new |
| Invesco Ltd. | 4.5M | $62M | 2.78% | +43.2% |
| WELLINGTON MANAGEMENT GROUP LLP | 3.9M | $54M | 2.41% | +78.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 3.6M | $50M | 2.27% | +3.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.13 | — | $70.9M | +35.1% |
| 2025-12-31 | 2026-02-05 | — | — | $71.7M | +51.0% |
| 2025-09-30 | 2025-11-05 | $0.06 | — | $94.0M | +102.4% |
| 2025-06-30 | 2025-08-05 | −$0.17 | — | $58.9M | +36.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Immune Medicine Service Revenue 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
